( NASDAQ-NMS:ARRY )

News from Array BioPharma Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 16, 2018, 17:17 ET Array BioPharma Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the Combination of Encorafenib and Binimetinib in Patients with BRAF-mutant Melanoma at 2018 ASCO Annual Meeting

Array BioPharma Inc. (Nasdaq: ARRY) announced that it will present data from the Phase 3 COLUMBUS trial of encorafenib and binimetinib in advanced...


May 09, 2018, 08:00 ET Array BioPharma Reports Financial Results For The Third Quarter of Fiscal 2018

Array BioPharma Inc., (Nasdaq: ARRY) today reported results for its third quarter of fiscal 2018 and provided an update on the progress of its key...


Apr 30, 2018, 16:05 ET Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2018 On May 9, 2018

Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2018 and hold a conference call to discuss those...


Mar 05, 2018, 16:01 ET Array BioPharma To Present At The Cowen 38th Annual Healthcare Conference

Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Cowen 38th Annual Healthcare...


Feb 07, 2018, 16:05 ET Array BioPharma To Present At The LEERINK Partners 7th Annual Global Healthcare Conference

Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the LEERINK Partners 7th Annual...


Feb 06, 2018, 08:05 ET Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018

Array BioPharma Inc. (Nasdaq: ARRY) today reported results for its second quarter of fiscal 2018 and provided an update on the progress of its key...


Feb 06, 2018, 08:00 ET Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial

Array BioPharma Inc. (Nasdaq: ARRY) and Pierre Fabre today announced results of the planned analysis of overall survival (OS) from the pivotal...


Jan 30, 2018, 09:00 ET Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2018 On February 6, 2018

Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2018 and hold a conference call to discuss...


Jan 20, 2018, 10:05 ET Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer in Updated Safety Lead-In Results from BEACON Phase 3 Trial

Array BioPharma Inc. (Nasdaq: ARRY) and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC...


Jan 20, 2018, 10:05 ET Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer in Updated Safety Lead-In Results from BEACON Phase 3 Trial

Array BioPharma Inc. (Nasdaq: ARRY) and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC...


Jan 02, 2018, 10:00 ET Array BioPharma To Present At The Annual J.P. Morgan Healthcare Conference

Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Annual J.P. Morgan Healthcare...


Dec 19, 2017, 08:00 ET Array BioPharma Announces Strategic Collaboration with Pfizer

Array BioPharma (Nasdaq: ARRY) announced today that it has entered into a clinical trial collaboration agreement with Pfizer to investigate the...


Dec 04, 2017, 19:00 ET Array BioPharma Announces Redemption of All Remaining 3.00% Convertible Senior Notes Due 2020

Array BioPharma Inc. (Nasdaq: ARRY) ("Array" or the "Company") today announced that it has called for redemption approximately $6.2 million of its...


Nov 22, 2017, 10:00 ET Array BioPharma To Present At The 2017 Piper Jaffray Healthcare Conference

Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the 2017 Piper Jaffray...


Nov 22, 2017, 09:37 ET Array BioPharma To Present At The 2017 Piper Jaffray Healthcare Conference

Array BioPharma Inc. (Nasdaq: ARRY) today announced that Chief Executive Officer, Ron Squarer, will present at the 2017 Piper Jaffray Healthcare...


Nov 16, 2017, 17:54 ET Array BioPharma Announces Private Exchange of $107 Million of its 3.00% Convertible Senior Notes due 2020 for its 2.625% Convertible Senior Notes due 2024 and Shares of its Common Stock

Array BioPharma Inc. (Nasdaq: ARRY) ("Array" or the "Company") announced today that it has entered into separate, privately negotiated exchange...


Nov 13, 2017, 08:00 ET Array BioPharma Reports Initial Results From Novel Immunotherapy Combination At The Society For Immunotherapy Of Cancer (SITC) 32nd Annual Meeting

Array BioPharma Inc. (Nasdaq: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small...


Oct 31, 2017, 08:00 ET Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2018

Array BioPharma Inc. (Nasdaq: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small...


Oct 24, 2017, 10:00 ET Array Biopharma To Report Financial Results For The First Quarter Of Fiscal 2018 On October 31, 2017

Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2018 and hold a conference call to discuss those...


Sep 19, 2017, 10:00 ET Array BioPharma To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference

Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the 2017 Cantor Fitzgerald...


Sep 19, 2017, 09:09 ET Array BioPharma Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Array BioPharma Inc. (Nasdaq: ARRY) announced today the closing of its underwritten public offering of 24,069,766 shares of its common...


Sep 14, 2017, 19:17 ET Array BioPharma Announces Pricing of Public Offering of Common Stock

Array BioPharma Inc. (Nasdaq: ARRY) announced today the pricing of an underwritten public offering of 20,930,232 shares of its common stock at a...


Sep 13, 2017, 16:01 ET Array BioPharma Announces Proposed Public Offering of Common Stock

Array BioPharma Inc. (Nasdaq: ARRY) today announced that it has commenced an underwritten public offering of $175,000,000 of shares of its common...


Sep 12, 2017, 09:09 ET Array BioPharma Announces FDA Acceptance For Review Of Binimetinib And Encorafenib New Drug Applications For Patients With Advanced BRAF-mutant Melanoma

Array BioPharma (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Applications...


Aug 30, 2017, 08:00 ET Array Biopharma To Present BEACON CRC Safety Lead-in And COLUMBUS Part 2 Results At European Society For Medical Oncology Congress (ESMO)

Array BioPharma Inc. (Nasdaq: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small...